Section Arrow
CRBU.NASDAQ
- Caribou Biosciences
Quotes are at least 15-min delayed:2025/12/26 05:59 EST
Pre Market
Last
 1.72
0 (0.00%)
Bid
1.67
Ask
1.77
High 1.75 
Low 1.71 
Volume 602 
Regular Hours (Closed)
Last
 1.72
+0.06 (+3.61%)
Day High 
1.73 
Prev. Close
1.66 
1-M High
1.9699 
Volume 
333.00K 
Bid
1.67
Ask
1.77
Day Low
1.6401 
Open
1.65 
1-M Low
1.62 
Market Cap 
155.16M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 1.73 
20-SMA 1.8 
50-SMA 2.08 
52-W High 3.535 
52-W Low 0.66 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-1.70/-1.27
Enterprise Value
180.22M
Balance Sheet
Book Value Per Share
1.52
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
9.99M
Operating Revenue Per Share
0.37
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
APLTApplied Therapeutics0.1154-0.0003-0.26%-- 
Pre Market 0.1137 -0.0017 -1.47%
INDPIndaptus Therapeutics Inc2.65+0.7+35.90%-- 
Pre Market 2.5 -0.15 -5.66%
OMEROmeros Corp15.36+6.61+75.54%-- 
Pre Market 14.85 -0.51 -3.32%
DRMADermata Therapeutics Inc2.37+0.33+16.18%0.13PE
Pre Market 2.28 -0.09 -3.80%
CTXRCitius Pharmaceuticals Inc0.8006-0.2394-23.02%-- 
Pre Market 0.8069 +0.0063 +0.79%
Industry overview quotes are at least 15 minutes delayed
Business Description
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPRplatform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies. The company operates and manage business as one reportable operating segment, which is the business of developing a pipelineof allogeneic CAR-T and CAR-NK cell therapies. Geographically, it operates in United States and Rest of the World, of which United States derives maximum revenue.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.